Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2498-2507

  Zamek Gliszczynski, Maciej J ^a   Ruterbories, Kenneth J ^a   Ajamie, Rose T ^a   Wickremsinhe, Enaksha R ^a   Pothuri, Lavanya ^b   Rao, Mukkavilli V S ^b   Basavanakatti, Vinay N ^b   Pinjari, Jakir ^b   Ramanathan, Vikram K ^b   Chaudhary, Ajai K ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Advinus Therapeutics Private Limited Bangalore   (India)

Author keywords

Drug interactions; Hepatic clearance; Protein binding; Renal clearance

Indexed keywords

ARIPIPRAZOLE; ATENOLOL; ATORVASTATIN; CLOPIDOGREL; DICLOFENAC; DILTIAZEM; ESOMEPRAZOLE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IMIPRAMINE; INDOMETACIN; LOPERAMIDE; MIDAZOLAM; MONTELUKAST; NELFINAVIR; OLANZAPINE; QUETIAPINE; QUINIDINE; ROSUVASTATIN; SERTRALINE; VALSARTAN; WARFARIN;

ANALYTIC METHOD; ARTICLE; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; EQUILIBRIUM DIALYSIS; HUMAN; ISOTOPE LABELING; KIDNEY CLEARANCE; LIVER CLEARANCE; METHODOLOGY; PLASMA PROTEIN BINDING; QUANTITATIVE ANALYSIS; RADIOCHEMISTRY; RELIABILITY; VALIDATION STUDY;

EID: 79954501848     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22452     Document Type: Article

References (38)

1. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215-236.
2. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. 2009. Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49(5):513-533.
3. Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM. 2007. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: Assessment of unbound brain EC50, u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 323(1):346-355.
4. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. 2006. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316(1):336-348.
5. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. 2003. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res 58(1):32-45.
6. Tang H, Mayersohn M. 2005. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33(9):1297-1303.
7. Howard ML, Hill JJ, Galluppi GR, McLean MA. 2010. Plasma protein binding in drug discovery and development. Comb Chem High Throughput Screen 13(2):170-187.
8. Banker MJ, Clark TH, Williams JA. 2003. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92(5):967-974.
9. Kariv I, Cao H, Oldenburg KR. 2001. Development of a high throughput equilibrium dialysis method. J Pharm Sci 90(5):580-587.
10. Waters NJ, Jones R, Williams G, Sohal B. 2008. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci 97(10):4586-4595.
11. European Medecines Agency. 2010. Guideline on the Investigation of Drug Interactions. EMA website At: (accessed September 2010).
12. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 2003. Guidance for Industry. Pharmacokinetics in Patients with Impaired Hepatic Function-Study Design, Data Analysis, and Implications for Dosing and Labeling. US FDA webiste At: (accessed September 2010).
13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2010. Guidance for Industry. Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Implications for Dosing and Labeling. US FDA webiste At: .
14. Pfizer Inc. 2009. Lipitor (atorvastatin calcium) Prescribing Information. At: (accessed September 2010).
15. Sanofi Pharma Bristol-Myers Squibb. 2009. Plavix (clopidogrel) Product Information. At: (accessed September 2010).
16. GlaxoSmithKline. 2010. Advair Diskus (fluticasone propionate and salmetrol inhalation powder) Prescribing Information. At: (accessed September 2010).
17. Manchee GR, Barrow A, Kulkarni S, Palmer E, Oxford J, Colthup PV, Maconochie JG, Tarbit MH. 1993. Disposition of salmeterol xinafoate in laboratory animals and humans. Drug Metab Dispos 21(6):1022-1028.
18. Novartis. 2010. Diovan (valsartan and hydrochlorothiazide) Prescribing Information. At: (acessed September 2010).
19. Otsuka Pharmaceutical Co. 2009. Abilify (ariprazole) Prescribing Information. At: (accessed September 2010).
20. AstraZeneca Pharmaceuticals LP. 2010. Nexium (esomeprazole magnesium) Prescribing Information. At: (accessed September 2010).
21. Eli Lilly and Company. 2010. Zyprexa (olanzapine) Prescribing Information. At: (accessed September 2010).
22. AstraZeneca Pharmaceuticals LP. 2010. Seroquel (quetiapine fumerate) Prescribing Information. At: (accessed September 2010).
23. AstraZeneca Pharmaceuticals LP. 2010. Crestor (rosuvastatin calcium) Prescribing Information. At: (accessed September 2010).
24. Merck & Co, Inc. 2010 Singulair (montelukast sodium) Prescribing Information. At: (accessed September 2010).
25. Novartis. 2009. Voltaren (diclofenac sodium) Prescribing Information. At: (accessed September 2010).
26. Aguron Pharmaceuticals, Inc. 2010. Viracept (nelfinavir mesylate) Prescribing Information. At: (accessed September 2010).
27. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 2006. Guidance for Industry. Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling. US FDA website. At: .
28. Thummel KE, Shen DD, Isoherranen N, Smith HE. 2006. Design and optimization of dosage regimens: Pharmacokinetic data. In Goodman & Gilman's the pharmacological basis of therapeutics; Brunton LL, Lazo JS, Parker KL, Eds. 11 ed. New York: McGraw-Hill.
29. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. 2000. Bioanalytical method validation-A revisit with a decade of progress. Pharm Res 17(12):1551-1557.
30. Wieling J, Tump C. 2004. An empirical study on the impact of bioanalytical method variability on estimation of PK parameters. Chromatographia 59:S187-S191.
31. AstraZeneca Pharmaceuticals LP. 2008. Tenormin (atenolol) Prescribing Information. At: (accessed September 2010).
32. Abbott Laboratories. 2007. Cardizem LA (diltiazem hydrochloride) Prescribing Information. At: (accessed September 2010).
33. Merck & Co, Inc. 2007. Indocin (indomethacin) Prescribing Information. At: (accessed September 2010).
34. Martindale. 1989. The extra pharmacopoeia. 29th ed. London, UK: The Pharmaceutical Press.
35. Watson Pharmaceuticals, Inc. 2005. Quinidine Sulfate (quinidine sulfate tablets) Prescribing Information. (accessed September 2010).
36. Pfizer, Inc. 2008. Zoloft (sertraline hydrochloride) Prescribing Information. At: (accessed September 2010).
37. Bristol-Myers Squibb. 2010. Coumadin (warfarin sodium) Prescribing Information. At: (accessed September 2010).
38. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. 2004. Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32(11):1201-1208.